Immunological defects in mice with a targeted disruption in Bcl-3

Genes and Development

Volumn 11, Issue 2, 1997, Pages 187-197

  Schwarz, Edward M ^a   Krimpenfort, Paul ^b   Berns, Anton ^b   Verma, Inder M ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Gene targeting; germinal centers; immune deficiency; NF B I B; pathogenesis

Indexed keywords

ONCOPROTEIN;

ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; GENE DISRUPTION; GENE TARGETING; HUMORAL IMMUNE DEFICIENCY; LISTERIA MONOCYTOGENES; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTO ONCOGENE; STREPTOCOCCUS PNEUMONIAE; T LYMPHOCYTE SUBPOPULATION;

ANIMALIA; LISTERIA MONOCYTOGENES; STREPTOCOCCUS PNEUMONIAE;

EID: 0031045073     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.11.2.187     Document Type: Article

References (43)

1. Adra, C.N., P.H. Boer, and M.W. McBurney. 1987. Cloning and expression of the mouse pgk-1 gene and the nucleotidc sequence of its promoter. Gene 60: 65-74.
2. Bancroft, G.J., R.D. Schreiher, and E.R. Unanue. 1991. Natural immunity: A T-cell independent pathway of macrophage activation, defined in the scid mouse, Immunol. Rev. 124: 5-24.
3. Barroga, C.F., J.K. Stevenson, E.M. Schwarz, and I.M. Verma. 1995. Constitutive phosphorylation of I kappa B alpha by casein kinase II. Proc. Natl. Acad. Sci. 92: 7637-7641.
4. Beg, A.A., W.C. Sha, R.T. Bronson, and D. Baltimore. 1995a. Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in IκBα-deficient mice. Genes & Dev. 9: 2736-2746.
5. Beg, A.A., W.C. Sha, R.T. Bronson, S. Ghosh, and D. Baltimore. 1995b. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 376: 167-170.
6. Bours, V., G. Franzoso, V. Azarenko, S. Park, T. Kanno, K. Brown, and U. Siebenlist. 1993. The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell 72: 729-739.
7. Caamano, J.H., P. Perez, S.A. Lira, and R. Bravo. 1996. Constitutive expression of Bcl-3 in thymocytes increases the DNA binding of NF-kB1 (p50) homodimers in vivo. Mol. Cel. Biol. 16: 1342-1348.
8. Chiao, P.J., S. Miyamoto, and I.M. Verma. 1994. Autoregulation of I kappa B alpha activity. Proc. Natl. Acad. Sci. 91: 28-32.
9. Crowe, P.D., T.L. VanArsdale, B.N. Walter, C.F. Ware, C. Hession, B. Ehrenfels, J.L. Browning, W.S. Din, R.G. Goodwin, and C.A. Smith. 1994. A lymphotoxin-beta-specific receptor [see Comments). Science 264: 707-710.
10. Dai, Y., E.M. Schwarz, D. Gu, W.W. Zhang, N. Sarvetnick, and I.M. Verma. 1995. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc. Natl. Acad. Sci. 92: 1401-1405.
11. Franzoso, G., V. Bours, S. Park, M. Tomita-Yamaguchi, K. Kelly, and U. Siebenlist. 1992. The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 359: 339-342.
12. Franzoso, G., V. Bours, V. Azarenko, S. Park, M. Tomita-Yamaguchi, T. Kanno, K. Brown, and U. Siebenlist. 1993. The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J. 12: 3893-3901.
13. Fujita, T., G.P. Nolan, H.C. Liou, M.L. Scott, and D. Baltimore. 1993. The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κ B p50 homodimers. Genes & Dev. 7: 1354-1363.
14. Hatada, E.N., A. Nieters, F.G. Wulczyn, M. Naumann, R. Meyer, G. Nucifora, T.W. McKeithan, and C. Scheidereit. 1992. The ankyrin repeat domains of the NF-kappa B precursor p 105 and the protooncogene bcl-3 act as specific inhibitors of NF-kappa B DNA binding. Proc. Natl. Acad. Sci. 89: 2489-2493.
15. Hooper, M., K. Hardy, A. Handyside, S. Hunter, and M. Monk. 1987. HPRT-deficient (Lesch-Nyhan) mouse embryos derived from germline colonization by cultured cells. Nature 326: 292-295.
16. Inoue, J., T. Takahara, T. Akizawa, and O. Hino. 1993. Bcl-3, a member of the I kappa B proteins, has distinct specificity towards the Rel family of proteins. Oncogene 8: 2067-2073.
17. Kawahe, T., T. Naka, K. Yoshida, T. Tanaka, H. Fujiwara, S. Suematsu, N. Yoshida, T. Kishimoto, and H. Kikutani. 1994. The immune responses in CD40-deficient mice: Impaired immunoglobulin class switching and germinal center formation. Immunity 1: 167-178.
18. Kerr, L.D., C.S. Duckett, P. Wamsley, Q. Zhang, P. Chiao, G Nabel, T.W. McKeithan, P.A. Baeuerle, and I.M. Verma. 1992. The proto-oncogene bcl-3 encodes an Iκ B protein. Genes & Dev. 6: 2352-2363.
19. Kim, U., X.F. Qin, S. Gong, S. Stevens, Y. Luo, M. Nussenzweig, and R.G. Roeder. 1996. The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes. Nature 383: 542-547.
20. Kitamura, D., J. Roes, R. Kuhn, and K. Rajewsky. 1991. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin μ chain gene. Nature 350: 423-426.
21. Kontgen, F., R.J. Grumont, A. Strasser, D. Metcalf, R. Li, D. Tarlinton, and S. Gerondakis. 1995. Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression. Genes & Dev. 9: 1965-1977.
22. Lenardo, M. and U. Siebenlist. 1994. Bcl-3-mediated nuclear regulation of the NF-kappa B trans-activating factor. Immunol. Today 15: 145-147.
23. Mims, C.A. 1990. The pathogenesis of infectious disease, Academic Press, San Diego, CA.
24. Miyamoto, S. and I.M. Verma. 1995. Rel/NF-kappa B/I kappa B story. Adv. Cancer Res. 66: 255-292.
25. Miyamoto, S., P.J. Chiao, and I.M. Verma 1994a. Enhanced I kappa B alpha degradation is responsible for constitutive NF-kappa B activity in mature murine B-cell lines. Mol. Cell. Biol. 14: 3276-3282.
26. Miyamoto, S., M. Maki, M.J. Schmitt, M. Hatanaka, and I.M. Verma. 1994b. Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc. Natl. Acad. Sci. 91: 12740-12744.
27. Miyamoto, S., M.J. Schmitt, and I.M. Verma. 1994c. Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc. Natl. Acad. Sci. 91: 5056-5060.
28. Miyamoto, S., K. Cauley, and I.M. Verma. 1995. Ultraviolet cross-linking of DNA binding proteins. Methods Enzymol. 254: 632-641.
29. Naumann, M., F.G. Wulczyn, and C. Scheidereit. 1993. The NF-kappa B precursor p105 and the proto-oncogene product Bcl-3 are I kappa B molecules and control nuclear translocation of NF-kappa B. EMRO J. 12: 213-222.
30. Neumann, B., A. Luz, K. Pfeffer, and B. Holzmann. 1996. Defective peyer's patch organogenesis in mice lacking the 55-kD receptor for tumor necrosis factor. J. Exp. Med. 184: 259-264.
31. Nolan, G.P., T. Fujita, K. Bhatia, C. Huppi, H.C. Liou, M.L. Scott, and D. Baltimore. 1993. The bcl-3 proto-oncogene encodes a nuclear I kappa B-like molecule that preferentially interacts with NF-kappa B p50 and p52 in a phosphorylation-dependent manner. Mol. Cell. Biol. 13: 3557-3566.
32. Ohno, H., G. Takimoto, and T.W. McKeithan. 1990. The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 60: 991-997.
33. Rajewsky, K. 1996. Clonal selection and learning in the antibody system. Nature 381: 751-758.
34. Robanus Maandag, E.C., M. van der Valk, M. Vlaar, C. Feltkamp, J. O'Brien, M. van Roon, N. van der Lugt, A. Berns, and H. te Riele. 1994. Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J. 13: 4260-4268.
35. Schubart, D., A. Rolink, M. Kosco-Vilbois, F. Botteri, and P. Matthias. 1996. B-cell-specific coactivator OBF-1/OCA-B/ Bobl required for immune response and germinal centre formation. Nature 383: 538-542.
36. Schwarz, E.M., P. Salgame, and B.R. Bloom. 1993. Molecular regulation of human interleukin 2 and T-cell function by interleukin 4. Proc. Natl. Acad. Sci. 90: 7734-7738.
37. Schwarz, E.M., D. Van Antwerp, and I.M. Verma. 1996. Constitutive phosphorylation of IkBa by casein kinase II occurs preferentially at serine 293: requirement for deradation of free IkBa. Mol. Cell. Biol. 16: 3554-3559.
38. Sha, W.C., H.C. Liou, E.I. Tuomanen, and D. Baltimore. 1995. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 80: 321-330.
39. te Riele, H., E.C. Robanus Maandag, and A. Berns. 1992. Highly efficient gene targeting in embryonic stem cells through homologous recombination with isogenic DNA constructs. Proc. Natl. Acad. Sci. 89: 5128-5132.
40. Verma, I.M., J.K. Stevenson, E.M. Schwarz, D. Van Antwerp, and S. Miyamoto. 1995. Rel/NF-κ B/I κ B family: Intimate tales of association and dissociation. Genes & Dev. 9: 2723-2735.
41. Welh, F., D. Carrasco, S.K. Durham, D.S. Barton, C.A. Rizzo, R. Ryseck, S.A. Lira, and R. Bravo. 1995. Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-kB/Rel family. Cell 80: 331-340.
42. Wulczyn, F.G., M. Naumann, and C. Scheidereit. 1992. Candidate proto-oncogene bcl-3 encodes a subunit-specific inhibitor of transcription factor NF-kappa B. Nature 358: 597-599.
43. Xu, J., T.M. Foy, J.D. Laman, E.A. Elliott, J.J. Dunn, T.J. Waldschmidt, J. Elsemore, R.J. Noelle, and R.A. Flavell. 1994. Mice deficient for the CD40 ligand. Immunity 1: 423-431.